CN100348259C - Medicine composition for raising immunity and its prepn and application - Google Patents
Medicine composition for raising immunity and its prepn and application Download PDFInfo
- Publication number
- CN100348259C CN100348259C CNB2005101155693A CN200510115569A CN100348259C CN 100348259 C CN100348259 C CN 100348259C CN B2005101155693 A CNB2005101155693 A CN B2005101155693A CN 200510115569 A CN200510115569 A CN 200510115569A CN 100348259 C CN100348259 C CN 100348259C
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- extracting solution
- group
- radix ginseng
- immunity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a medical composition for enhancing immunity, which is prepared from raw materials according to proportion by weight: 1 to 30 shares of ginseng, 10 to 90 shares of astragalus root, 5 to 60 shares of glossy privet fruit, 5 to 45 shares of wolfberry fruit, 10 to 90 shares of wild buckwheat and 1 to 30 shares of zedoary. By the certification of clinical tests, the medical composition of the present invention has an obvious effect of enhancing the immunity of human bodies and has a good effect of enhancing the immunity of tumor patients, particularly the tumor patients treated by radiotherapy and chemotherapy.
Description
Technical field
The present invention relates to improve the pharmaceutical composition of immunity, relate in particular to and be used for pharmaceutical composition that improves body's immunity of tumor patient and its production and application.
Background technology
Immunity is meant body identification and gets rid of antigenicity foreign body function that promptly body is distinguished own and non-function.Immunity mainly refers to the resistance of the anti-pathogenic microorganism of human body, and making the morbific various pathogen of people is a kind of of antigenicity foreign body, and immunity still is the important foundation stone that human body is kept ecological balance.Immunity is low is embodied in and often feels tired, easy to catch cold, wound infection, gastrointestinal upset and be subject to infectious disease attack etc. easily.
The immunity that improves human body is very important for the patient who suffers from multiple disease, especially tumor, and the immunity that improves body can significantly promote treatment of diseases and rehabilitation of patients.
See by the morbidity of the traditional Chinese medical science, the generation of any disease nothing more than just, the factor of evil two aspects.Generation about tumor, Chinese medicine is thought, is because under the state of yin and yang imbalance, qi and blood disorder, QI of five ZANG-organs disorder, external pathogen avails oneself of the opportunity to get in, destroyed the five internal organs normal physiological function, material bases such as loss human body essence, gas, blood, body fluid cause pathological changes such as the stagnation of QI, blood stasis, expectorant are coagulated, wetly stopped, poison is poly-, produce blood stasis, phlegm retention, poisonous substance etc., for a long time it, these pathological products are glued mutually, form tangible swollen thing, so tumor has just taken place.The inducement of the existing six climate exopathogens of the generation of tumor, seven emotions, impairment caused by overstrain, organism imbalance of YIN and YANG, QI and blood more have the existence of cancer poison against disorderly unusual again.Cancer poison oncogenic process is exactly constantly to consume body essence, gas, blood, body fluid, has destroyed the balance coordination of human body yang blood and qi, has reduced the anti-cancer ability of body, the diffusion rapidly of cancer poison, and the depletion that finally causes healthy energy is until death.
The common clinical treatment rule of tumor has: the body resistance strengthening and constitution consolidating method, activating blood circulation to dissipate blood stasis method, method of dissipating heat and detoxifying, hard masses softening and resolving method and treating the poisonous disease with poisonous drugs method etc.Wherein the body resistance strengthening and constitution consolidating is the cardinal principle of Chinese traditional treatment tumor.The positive deficiency of vital energy is the key factor that cancer takes place, and can occur the card of a series of deficiency of vital QI in the generation evolution of malignant tumor.As lustreless complexion, indigestion and loss of appetite abdominal distention, loose stool diarrhoea, pale tongue with thin fur, the weakness of the spleen and stomach symptom of thready pulse; Or see pharyngoxerosis, and the night sweat seminal emission, dysphoria with feverish sensation in the chest palms and soles, the red tongue tongue is few, thready and rapid pulse and having a dizzy spell, soreness of waist tinnitus, the dim eyesight order is puckery, the YIN fluid deficiency of deep red tongue tongue light and the card of the hepatic and renal YIN deficiency.Also aversion to cold and cold limbs can appear, soreness of the waist and knees, and pale complexion, clear urine in large amounts, big loose stool is thin, and light red tongue is fat, and the kidney yang of deep-thready pulse is lost the card of void.Reach an advanced stage and the cancer cachexia performance more can occur.According to treatment must aim at the pathogenesis of disease, deficiency syndrome should be treated by tonifying method, decrease benefit then principle, give replenishing QI to invigorate the spleen, enriching yin and nourishing kidney, warming and recuperating the kidney-YANG, treatments such as tonifying both YIN and YANG to improve Abwehrkraft des Koepers and immunologic function, improve symptom, the raising curative effect.In the developing of tumor, evil poison, blood stasis, expectorant can occur and pathological product such as coagulate, show as the card of deficiency in origin and excess in superficiality.Can be according to the weakened body resistance and domination of pathogen biased, giving eliminating evil is main holding concurrently to set upright, strengthening vital QI to eliminate pathogenic factors is laid equal stress on, setting upright is main holding concurrently with eliminating evil treatment.Heresy is gone to then Zhengan County, eliminating evilly promptly sets upright, and just containing then can be eliminating evil, and weakened body resistance then evil the love set upright method through treatment all the time.Therefore the body resistance strengthening and constitution consolidating is the cardinal principle of Chinese traditional treatment tumor.Operation, chemicotherapy etc. are sent an expedition against therapy and also can be damaged the human righteousness, reduce immunologic function, correct the unbalance of negative and positive in the body as cooperating traditional Chinese medical science the body resistance strengthening and constitution consolidating, not only alleviate side reaction, also can improve curative effect simultaneously.Studies show that in a large number; developing of the body resistance strengthening and constitution consolidating energy prophylaxis of cancer; the human body immunity improving function; the endocrine regulation system balancing; promote hemopoietic and protection bone marrow and conscience kidney, the infringement that alleviates chemicotherapy strengthens the ability of digesting and assimilating; the function that excites and improve the automatic adjusting of body and control automatically heightens the effect of a treatment.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition that improves immunity, this pharmaceutical composition is applicable to human body immunity improving power, is specially adapted to improve tumor patient, especially through the immunity of organisms of the tumor patient of chemicotherapy treatment.
The present invention also aims to provide the preparation method and the application thereof of aforementioned pharmaceutical compositions.
Technical assignment of the present invention is achieved through the following technical solutions.
The invention provides a kind of pharmaceutical composition that improves immunity, this pharmaceutical composition is by comprising that following materials of weight proportions makes: Radix Ginseng 1-30 part, Radix Astragali 10-90 part, Fructus Ligustri Lucidi 5-60 part, Fructus Lycii 5-45 part, Rhizoma Fagopyri Dibotryis 10-90 part, Rhizoma Curcumae 1-30 part; Preferably ginseng 10-20 part, Radix Astragali 20-40 part, Fructus Ligustri Lucidi 10-25 part, Fructus Lycii 10-30 part, Rhizoma Fagopyri Dibotryis 20-50 part, Rhizoma Curcumae 5-15 part; More preferably Radix Ginseng is 10 parts, 30 parts of the Radixs Astragali, 20 parts of Fructus Ligustri Lucidi, 15 parts of Fructus Lycii, 30 parts of Rhizoma Fagopyri Dibotryiss, 10 parts of Rhizoma Curcumae.
Wherein, Radix Ginseng is preferably Radix Ginseng.
Above-mentioned raw materials Radix Ginseng, the Radix Astragali, Fructus Ligustri Lucidi, Fructus Lycii, Rhizoma Fagopyri Dibotryis and Rhizoma Curcumae can be bought from regular pharmacy, and specification meets national medical standard.
Pharmaceutical composition of the present invention can be made various regular dosage forms, as tablet, granule, powder, oral liquid, capsule, pill etc., preferred particulates agent, capsule and oral liquid.
The preparation method and the technology of several concrete dosage forms are provided below.
The invention provides the preparation method of aforementioned pharmaceutical compositions granule, this method may further comprise the steps: (1) uses water extraction with Radix Ginseng, Fructus Lycii and Rhizoma Fagopyri Dibotryis, extracting solution is concentrated, and drying, and be crushed and screened into medicated powder; (2) Radix Astragali and Fructus Ligustri Lucidi are extracted with alcoholic solution, extracting solution is reclaimed ethanol concentrate, drying, and be crushed and screened into medicated powder; (3) Rhizoma Curcumae is extracted with vapor distillation, gained extractive of volatile oil beta-cyclodextrin inclusion compound is made clathrate; (4) behind the clathrate mix homogeneously with the medicated powder of the medicated powder of step (1), (2) and (3), make granule with conventional method.
Perhaps, step (1) can concentrate extracting solution for Fructus Lycii and Rhizoma Fagopyri Dibotryis are used water extraction, and drying is crushed and screened into medicated powder, and Radix Ginseng directly is crushed and screened into medicated powder, and both mixings are obtained mixed-powder.What use in step this moment (4) is this mixed-powder.
Can obtain capsule with the granule drying of above-mentioned gained, granulate with in the capsule shells after the fill.
The present invention also provides the preparation method of this drug composition oral liquid, and this method comprises: (1) uses water extraction with Radix Ginseng, Fructus Lycii and Rhizoma Fagopyri Dibotryis, extracting solution, extracting solution concentrate concentrated solution; (2) with the Radix Astragali and Fructus Ligustri Lucidi ethanol extraction, extracting solution is centrifugal, gets supernatant concentration and gets concentrated solution; (3) Rhizoma Curcumae is extracted volatile oil, get extractive of volatile oil; (4) directly or again add correctives and/or antiseptic as required after the extracting solution of step (1), (2) and (3) is mixed after, the reuse conventional method is made oral liquid.
On the step (1), (2) and (3) basis of this medicament composition granule agent method of preparation, behind the clathrate mix homogeneously with the medicated powder of the medicated powder of step (1), (2) and (3), make tablet, pill etc. with conventional method.
The instructions of taking of pharmaceutical composition of the present invention is: by raw medicinal material weight, take 115g every day, be divided into 2-3 time and use warm water delivery service.Take 1-2 month continuously for one-period, can take continuously to consolidate curative effect.
The Radix Ginseng and the Radix Astragali are monarchs drug in the pharmaceutical composition of the present invention, and Fructus Lycii and Fructus Ligustri Lucidi are ministerial drugs, and Rhizoma Fagopyri Dibotryis is an adjuvant drug, and Rhizoma Curcumae is a messenger drug, and this compound basis is as follows:
Monarch drug----Radix Ginseng, the Radix Astragali: two medicines all have the effect that strengthens body immunity, and the effect that presses down tumor is indirectly arranged;
Ministerial drug----Fructus Lycii, Fructus Ligustri Lucidi: this two flavors medicine effect is kidney-boosting tonic, the cellular immune function that is significantly improved and improve the life quality effect;
Adjuvant drug----Rhizoma Fagopyri Dibotryis: function heat-clearing and toxic substances removing, activating blood circulation to dissipate blood stasis, modern pharmacy studies show that this medicament extract has tumor and the anti-tumor effect of directly pressing down, it is synthetic to suppress tumor cell DNA, and it can suppress the invasion and attack and the transfer of multiple oncocyte, and the minimum evidence of toxicity has the immunologic function facilitation, according to setting upright is main, pressing down tumor is auxilliary policy, and this medicine is made antineoplastic component, is the adjuvant drug in the side;
Messenger drug----Rhizoma Curcumae: Rhizoma Curcumae is an activating blood herbs, for gas medicine in the blood, makes it to tend to the target area as messenger drug, studies have shown that simultaneously the elemene composition has tangible tumor-inhibiting action in the Rhizoma Curcumae, uses it to kill two birds with one stone.
Pharmaceutical composition of the present invention has the effect of significant human body immunity improving power through clinical trial proof, and especially for improving tumor patient, particularly the immunity through the tumor patient of chemicotherapy treatment has extraordinary effect.
Pharmaceutical composition of the present invention is safe and effective through animal drug effect toxicological experiment proof.
The effect of pharmaceutical composition of the present invention is described below in conjunction with concrete test.
1. test objective
Observe drug regimen of the present invention to normal and chemotherapy effect of immunologic function, and the inhibitory action that mouse tumor is shifted.
2. test material
2.1 medicine
2.1.1 be subjected to the reagent thing
Drug regimen of the present invention
2.1.2 other drug and reagent
ZHENQI FUZHENG JIAONANG, Guizhou Xinbang Pharmacy Stock Co., Ltd's lot number: 20050604
Cyclophosphamide (cytoxon, CTX), Jiangsu Province Lianyungang Pharmaceutical Factory produces;
Cytosine arabinoside (cytarabine, ARA-C), pharmaceutical factory of Beijing Medical University produces;
The RPMI1640 culture fluid, CIBCO Laboratories produces;
ConA, Guangzhou the medical professionals produce;
MTT, Sino American Biotec produces;
Complement sensitization zymosan freeze-dried reagent, the Shanghai Changhai Hospital epi chamber is produced.
2.2 animal
Plant system: BALB/c mouse
Body weight: 18-20g
Sex: male and female half and half
Number of animals: 48
Plant system: Kunming mouse
Body weight: 20-22g
Sex: male and female half and half
Number of animals: 80
Plant system: C57 BL/6 mice
Body weight: 18-22g
Sex: female
Number of animals: 40
Plant system: the SD rat
Body weight: 200-250g
Sex: male and female half and half
Number of animals: 15
2.3 cell
The strain of murine melanoma B16 tumor
3. experimental technique
3.1 drug regimen of the present invention is to the BALB/c mouse Immune Effects
48 BALB/c mouse are divided into 6 groups at random, 8 every group. and (1) matched group (A group) gavages distilled water every day, continuously 7d; (2) the heavy dose of group of drug regimen of the present invention (40g/kg) (B group) gavages its solution every day, continuously 7d; (3) ZHENQI FUZHENG JIAONANG group (C group) gavages its solution every day; (4) CTX group (D group) is pressed 0.06g/kg (0.01ml/g) body weight, at the 6th day ip (lumbar injection); (5) drug regimen heavy dose of the present invention is share CTX group (E group), and each dosage and administration is respectively with B group and D group; (6) ZHENQI FUZHENG JIAONANG is share CTX group (F group), and each dosage and administration is respectively with C group and D group.Behind the last administration 24h, each is organized mice and carries out the eye socket sacrificed by exsanguination and get peripheral blood, put into anticoagulant tube, aseptic spleen and the peritoneal exudate cells got done the active detection of erythrocyte C3b receptor, splenocyte breeder reaction and the active detection of peritoneal macrophage (attached cell) C3b receptor respectively.
Detect 3.1.1 the erythrocyte C3b receptor is active
Erythrocyte is made into 1.25 * 10
7/ ml uses liquid, and complement sensitization zymosan is made into 1 * 10
8/ ml uses liquid, and two kinds are used liquid to mix by 1: 1, put 37 ℃ of water-baths 30 minutes, with the fixing smear of 0.25% glutaraldehyde, dyes, and microscopy is counted in 200 erythrocyte the rosette rate in conjunction with 3 above zymosans.
3.1.2 splenocyte breeder reaction
Spleen is ground, remove by filter erythrocyte, be made into 5 * 10 with RPMI-1640
8Individual/the ml splenocyte suspension, 40 hole plastic culture plates are cultivated, after every hole adds ConA, and CO
2Cultivate 72h in the incubator, measure the breeder reaction result with the MTT colorimetric analysis then.The average OD value of the average OD value * control wells of cell proliferative response rate (%)=experimental port
-1* 100%.
3.1.3 peritoneal macrophage C3b receptor activity
Aseptic absorption mouse peritoneal emigrated cell, drip on slide, under 37 ℃ of temperature, place 2h, wash away not attached cell, drip an amount of sensitization yeast, wash away unconjugated yeast behind 4 ℃ of following 1h, the fixing dyeing of 0.25% glutaraldehyde, microscopy calculates in 200 abdominal cavity attached cells the rosette rate in conjunction with 2 above zymosans.
3.2 drug regimen of the present invention is to the influence of acid nonspecific esterase (ANA E) labelling of mouse lymphocyte
40 Kunming mouses are divided into 4 groups at random, 10 every group.(1) matched group gavages distilled water every day, continuously 7d; (2) ZHENQI FUZHENG JIAONANG group gavages its solution every day, continuously 7d; (3) the heavy dose of group of drug regimen of the present invention (40g/kg) gavages its solution every day, continuously 7d; (4) drug regimen small dose group of the present invention (20g/kg) gavages its solution every day, continuously 7d.The tail vein is got blood smear behind last administration 24h, does ANA E dyeing, counts male T cell number of ANA E and ANA E+ lymphocyte percentage in 100 T lymphocytes under oily mirror, and calculates the ratio of TH and TS cell.
3.3 drug regimen of the present invention is to the influence of macrophage phagocytosis of mice
40 Kunming mouses, grouping and medication are the same, observe the situation that Turnover of Mouse Peritoneal Macrophages is engulfed chicken red blood cell (CRBC), calculate phagocytic index.
3.4 drug regimen of the present invention is to accepting lethal dose ARA-C mice existence test
40 Kunming mouses, be divided into 4 groups at random, grouping and medication are the same, and 4 groups all respectively at the 0th, 8, the every Mus 12ml of 24h lumbar injection ARA-C, the two groups of oral corresponding dosage of 2h drug regimen extracting solution of the present invention before injecting ARA-C of heavy dose of group of drug regimen of the present invention (40g/kg) and small dose group (20g/kg), after every other day once, totally 5 times, observed for 2 weeks, write down each treated animal existence situation.
3.5 suppressing B16 cell lung, drug regimen of the present invention shifts test
Rat is pressed the continuous 10d of 50mg/kg dosage gastric infusion every day, 2～3h after last administration, and the socket of the eye venous plexus is got blood system and is pastille serum from serum, through 56 ℃, 30min, freezing preservation is standby after the deactivation.With normal rat serum is contrast.
The strain of murine melanoma B16 tumor, RPMI 1640 adds the cultivation of going down to posterity of 10% hyclone culture fluid.
Be that the tumor cell of 24 hours In vitro culture of pastille serum In vitro culture B16 cytosis of 5%, 10%, 20% and 30% is collected with trypsinization with final concentration respectively, HBSS washes 3 times, makes 1 * 10
5/ mL cell suspension, in the tail vein injected C57BL/6 mice body, every group of 6 animals were got Mus lung branch on count tuberosity after 3 weeks with 0.12ml.
4. result of the test
4.1 drug regimen of the present invention is to the BALB/c mouse Immune Effects
4.1.1 drug regimen of the present invention is to the active influence of Turnover of Mouse Peritoneal Macrophages C3b receptor
CTX group rosette rate numerical value is starkly lower than blank group (P＜0.05), share drug regimen group of the present invention and then makes rosette rate numerical value recover normal, and single rosette rate of using drug regimen of the present invention sees table 1 for details apparently higher than blank group (P＜0.05).
4.1.2 drug regimen of the present invention is to the influence of mouse boosting cell breeder reaction
CTX can make splenocyte response rate OD value significantly be lower than blank group (P＜0.05), share drug regimen of the present invention and can improve the OD value, but compare with the blank group, and difference is not obvious.Though use the OD value of drug regimen group of the present invention also to be lower than matched group, difference is not obvious, sees Table 1.
4.1.3 drug regimen of the present invention is to the active influence of mouse red blood cell C3b receptor
Each medication group is compared with the blank group, and rosette rate is height difference slightly, but difference not obvious (P＞0.05) sees Table 1.
Table 1 medicine is to the BALB/c mouse Immune Effects
| Group | Dosage and usage (g.kg-1.d-1) | Number of animals | Splenocyte breeder reaction rate (OD value) | C3b receptor activity (%) | |
| Peritoneal macrophage | Erythrocyte | ||||
| Matched group ZHENQI FUZHENG JIAONANG group drug regimen group of the present invention CTX group ZHENQI FUZHENG JIAONANG+CTX group | - 4.17×7，ig 2.32×7，ig 0.06×1，ip 4.17×7，ig 0.06×1，ip | 8 8 8 8 8 | 0.26±0.08 0.22±0.08 0.20±0.06 0.15±0.08 * 0.18±0.07 | 35.14±4.81 47.56±10.23 * 45.14±9.70 * 26.50±7.87 * 40.24±6.78 | 6.20±2.59 5.38±1.88 5.43±1.51 4.63±2.33 7.33±3.06 |
| CTX+ drug regimen group of the present invention | 2.32×7，ig 0.06×1，ip | 8 | 0.19±0.06 | 36.57±5.62 | 7.71±2.56 |
*Compare P＜0.05 with the normal group analog value;
*Compare P＜0.01 with the normal group analog value;
4.2 drug regimen of the present invention is to the influence of acid nonspecific esterase (ANAE) labelling of mouse lymphocyte
The ANA E positive rate of drug regimen group of the present invention is apparently higher than matched group (P＜0.01), and TH/TS ratio also apparently higher than matched group (P＜0.05), sees Table 2
Table 2 medicine is to the influence of lymphocyte ANAE labelling
| Group | Number of animals | The observation of cell number | Positive rate (%) | T H/T S | ||
| T H | T S | Add up to | ||||
| The heavy dose of group of matched group ZHENQI FUZHENG JIAONANG group small dose group | 10 10 10 10 | 3000 3000 3000 3000 | 20.4±2.11 41.4±3.57 39.6±4.77 35.5±5.33 | 25.7±3.26 33.3±3.24 30.6±4.05 28.9±3.12 | 46.1 74.7 ** 70.2 ** 64.4 ** | 0.79 1.24 ** 1.29 ** 1.23 * |
*Compare P＜0.05 with the normal group analog value;
*Compare P＜0.01 with the normal group analog value;
4.3 drug regimen of the present invention is to the influence of Turnover of Mouse Peritoneal Macrophages phagocytic function
Drug regimen of the present invention can make the Turnover of Mouse Peritoneal Macrophages phagocytic function obviously strengthen, and improves phagocytic index, sees Table 3
Table 3 medicine is to the influence of Turnover of Mouse Peritoneal Macrophages phagocytic function
| Group | Number of animals | The observation of cell number | Phagocytic rate (%) | Phagocytic index |
| The heavy dose of group of matched group ZHENQI FUZHENG JIAONANG group small dose group | 10 10 10 10 | 3000 3000 3000 3000 | 62.15±5.31 82.22±3.53 * 84.57±5.03 * 79.40±4.99 * | 0.814±0.066 1.740±0.054 1.784±0.134 1.700±0.120 |
*Compare P＜0.05 with the normal group analog value;
*Compare P＜0.01 with the normal group analog value;
4.4 drug regimen of the present invention is to accepting the influence of lethal dose ARA-C mice existence
Two group life of oral drug regimen solution of the present invention prolong apparently higher than matched group (P＜0.05), see Table 4
Table 4 medicine is to accepting the influence of lethal dose ARA-C mice existence
| Group | Number of animals | The animal dead number | The survival natural law |
| The heavy dose of group of matched group ZHENQI FUZHENG JIAONANG group small dose group | 10 10 10 10 | 2/8 2/8 2/8 3/7 | 6.7±1.25 12.2±1.16 * 11.9±1.44 * 11.2±1.40 * |
*Compare P＜0.05 with the normal group analog value;
4.5 suppressing B16 cell lung, drug regimen of the present invention shifts test
Pastille serum shifts inhibited to the lung tuberosity of B16 cell, variable concentrations pastille serum treatments B 16 cells 24 hours are dose dependent to the lung metastasis inhibition, see Table 5
The influence that table 5 medicine shifts murine melanoma B16 cell lung
| Serum content (%) | Lung shifts tuberosity (individual) | Suppression ratio (%) |
| 0 5 10 20 30 | 21.0±6.8 19.3±1.7 17.0±1.8 12.0±4.8 8.0±3.3 | - 8.0 19.0 43.0 62.0 |
5. discuss:
This experiment, is studied the effect of drug regimen raise immunity of the present invention as positive drug with ZHENQI FUZHENG JIAONANG, and the result has confirmed that drug regimen of the present invention has the function of tangible enhancing human body immunity ability.Experimental result shows that this invention drug regimen can obviously improve the active and peritoneal macrophage phagocytic function of Turnover of Mouse Peritoneal Macrophages C3b receptor, improve ANA E+T lymphocyte percentage in the mice peripheral blood, improve TH/TS ratio, show that all its specific immunity to body has potentiation.Peritoneal macrophage C3b receptor increased activity and phagocytic activity strengthen, and body is increased the phagocytosis of the tumor cell of sudden change formation.TH/TS ratio descends, and may cause body's immunity to go down, and raises then to cause immunologic function to increase.Drug regimen of the present invention significantly improves TH/TS ratio, shows that it has the effect that strengthens and regulate cellular immune function.
In addition, but experimental result shows drug regimen significant prolongation of the present invention and gives the life of cytosine arabinoside (ARA-C) with the lethal dose mice, may be the situation that chemotherapy obviously reduces ubiquitous cell of body and humoral immunoresponse(HI) and immunoregulation effect because this invention drug regimen can significantly improve, thereby keep the interior environment of body relatively stable.This experimental result shows that this invention drug regimen is to had the restitution of significant protective effect and pair cell immunologic hypofunction by the caused immunity degradation of chemotherapy, for clinical raising is put, chemotherapy patients's immunologic function provides foundation.
Drug regimen of the present invention suppresses result's demonstration that B16 cell lung shifts test, pastille serum shifts inhibited to the lung tuberosity of B16 cell, variable concentrations pastille serum treatments B 16 cells 24 hours are dose dependent to the lung metastasis inhibition, show this invention drug regimen also have antitumor patient postoperative recurrence except having the effect that strengthens and regulate immunologic function, suppress the effect that tumor cell shifts.
6. conclusion
This invention drug regimen has the effect of the attenuation synergistic after enhancing immunity, the chemotherapy, anti-postoperative recurrence, the transfer of inhibition tumor cell.
The specific embodiment
Below in conjunction with embodiment embodiments of the present invention are described, but these embodiment and unrestricted embodiments of the present invention.The present invention has multiple different embodiment, has more than to be limited to content described in this description.Those skilled in the art is under the present application mental condition, and the scheme of being finished should be within the scope of the invention.
Embodiment 1
Take by weighing Radix Ginseng 10g, Radix Astragali 30g, Fructus Ligustri Lucidi 20g, Fructus Lycii 15g, Rhizoma Fagopyri Dibotryis 30g and Rhizoma Curcumae 10g; Radix Ginseng, Fructus Lycii and Rhizoma Fagopyri Dibotryis are extracted three times with 440mL, the each extraction 2 hours, merge extractive liquid, and to be concentrated into relative density be 1.07g/ml, add an amount of 95% ethanol and make that to contain alcohol amount be 60%, standing over night, supernatant decompression recycling ethanol, 70 ℃ of vacuum dryings, pulverize, cross 80 mesh sieves, standby; With the Radix Astragali and Fructus Ligustri Lucidi 300mL 60% ethanol extraction twice, extracted 2 hours at every turn, merge extractive liquid,, decompression recycling ethanol, 70 ℃ of vacuum dryings are pulverized, and cross 80 mesh sieves, and are standby; Rhizoma Curcumae is added the water extraction volatile oil 7 hours of 80mL, and volatile oil is made clathrate with the beta-cyclodextrin inclusion compound of 2 times of amounts; Get above-mentioned two kinds of medicated powder and clathrate, add Icing Sugar and dextrin mixture (Icing Sugar: dextrin is 1: 1) and an amount of correctives (aspartame etc.) mixing of 30g, with an amount of 80% ethanol system soft material, cross 18 mesh sieves and granulate drying, granulate, add an amount of essence, obtain granule; Adorn capsule No. 0, get capsule.
Embodiment 2
Take by weighing Radix Ginseng 20g, Radix Astragali 30g, Fructus Ligustri Lucidi 25g, Fructus Lycii 10g, Rhizoma Fagopyri Dibotryis 20g and Rhizoma Curcumae 5g; Fructus Lycii and Rhizoma Fagopyri Dibotryis are used 25mL water extraction three times, the each extraction 3 hours, merge extractive liquid, and to be concentrated into relative density be 1.07g/ml, add 95% ethanol and be adjusted to that to contain the alcohol amount be 60%, standing over night is with the supernatant decompression recycling ethanol, 70 ℃ of vacuum dryings, pulverize, cross 80 mesh sieves, standby; Radix Ginseng is ground into powder, and the powder mixes of extract medicated powder and Radix Ginseng is even standby; Make granule or capsule with method similar to Example 1.
Embodiment 3
Take by weighing Radix Ginseng 30g, Radix Astragali 90g, Fructus Ligustri Lucidi 60g, Fructus Lycii 45g, Rhizoma Fagopyri Dibotryis 90g and Rhizoma Curcumae 30g; Radix Ginseng, Fructus Lycii and Rhizoma Fagopyri Dibotryis are used the water extraction 3 times of 1500mL respectively, the each extraction 4 hours, merge extractive liquid,, it is 1.07g/ml that extracting solution is concentrated into relative density, and add 95% ethanol and be adjusted to that to contain the alcohol amount be 60%, standing over night with the supernatant decompression recycling ethanol, gets concentrated solution; Use 60% alcoholic solution of 1000mL to extract twice the Radix Astragali and Fructus Ligustri Lucidi, extracted 2 hours at every turn, merge extractive liquid, got supernatant in centrifugal 30 minutes with 4000 rev/mins speed, reclaimed ethanol and got concentrated solution; Rhizoma Curcumae is added the water extraction volatile oil 8 hours of 300mL, extractive of volatile oil; With above-mentioned concentrated solution and extractive of volatile oil mixing, add proper honey, ultrafiltration adds 3 ‰ essence, aspartame etc. and carries out flavoring, and adds 1 ‰ sorbic acid and cook antiseptic, shakes up, and sterilization, fill become oral liquid.
Claims (9)
1. pharmaceutical composition that improves immunity, this pharmaceutical composition is made by following materials of weight proportions: Radix Ginseng 10-20 part, Radix Astragali 20-40 part, Fructus Ligustri Lucidi 10-25 part, Fructus Lycii 10-30 part, Rhizoma Fagopyri Dibotryis 20-50 part, Rhizoma Curcumae 5-15 part.
2. pharmaceutical composition as claimed in claim 1 is characterized in that, the weight proportion of raw material is: 10 parts of Radix Ginsengs, 30 parts of the Radixs Astragali, 20 parts of Fructus Ligustri Lucidi, 15 parts of Fructus Lycii, 30 parts of Rhizoma Fagopyri Dibotryiss, 10 parts of Rhizoma Curcumae.
3. as the pharmaceutical composition of claim 1 or 2, it is characterized in that described Radix Ginseng is a Radix Ginseng.
4. pharmaceutical composition as claimed in claim 1 is characterized in that, the dosage form of this pharmaceutical composition is any conventional peroral dosage form.
5. pharmaceutical composition as claimed in claim 4 is characterized in that, the dosage form of this pharmaceutical composition is granule, capsule or oral liquid.
6. prepare the method for the medicament composition granule agent of claim 1, this method may further comprise the steps:
(1) Radix Ginseng, Fructus Lycii and Rhizoma Fagopyri Dibotryis are used water extraction, get extracting solution, extracting solution concentrates, drying, and be crushed and screened into medicated powder; (2) with the Radix Astragali and Fructus Ligustri Lucidi ethanol extraction, extracting solution is centrifugal, gets supernatant concentration, drying, and be crushed and screened into medicated powder; (3) Rhizoma Curcumae is extracted volatile oil, get extractive of volatile oil, the extract obtained beta-cyclodextrin inclusion compound of using is made clathrate; (4) behind the clathrate mix homogeneously with the dry powder of the powder of step (1), (2) and (3), make granule with conventional method;
Perhaps, step (1) is that Fructus Lycii and Rhizoma Fagopyri Dibotryis are used water extraction, and extracting solution is concentrated, drying, and be crushed and screened into medicated powder, and Radix Ginseng is directly pulverized, be screened into medicated powder, and both mixings are obtained mixed-powder, what use in step this moment (4) is this mixed-powder.
7. the method for medicament composition capsule agent of preparation claim 1, this method may further comprise the steps: can obtain capsule with the granule drying of claim 6 gained, granulate with in the capsule shells after the fill.
8. the method for drug composition oral liquid of preparation claim 1, this method comprises: (1) use water extraction with Radix Ginseng, Fructus Lycii and Rhizoma Fagopyri Dibotryis, extracting solution, extracting solution concentrated concentrated solution; (2) with the Radix Astragali and Fructus Ligustri Lucidi ethanol extraction, extracting solution is centrifugal, gets supernatant concentration and gets concentrated solution; (3) Rhizoma Curcumae is extracted volatile oil, get extractive of volatile oil; (4) directly or again add correctives and/or antiseptic as required after the extracting solution of step (1), (2) and (3) is mixed after, the reuse conventional method is made oral liquid.
9. the application of pharmaceutical composition as claimed in claim 1 in the medicine of preparation raising immunity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101155693A CN100348259C (en) | 2005-11-07 | 2005-11-07 | Medicine composition for raising immunity and its prepn and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101155693A CN100348259C (en) | 2005-11-07 | 2005-11-07 | Medicine composition for raising immunity and its prepn and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1772268A CN1772268A (en) | 2006-05-17 |
| CN100348259C true CN100348259C (en) | 2007-11-14 |
Family
ID=36759520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101155693A Expired - Fee Related CN100348259C (en) | 2005-11-07 | 2005-11-07 | Medicine composition for raising immunity and its prepn and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100348259C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988828B (en) * | 2012-11-21 | 2014-09-17 | 光明食品集团云南石斛生物科技开发有限公司 | Preparation method of dendrobium officinale granula |
| CN109674985A (en) * | 2017-10-19 | 2019-04-26 | 新乡医学院三全学院 | Chinese medicine and preparation method thereof for treating intestinal adhesion |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1539458A (en) * | 2003-10-30 | 2004-10-27 | 吉林省辽源亚东药业股份有限公司 | Chinese materia medica preparation made from gen-seng and astragalus root for strengthening the body resistance and anti cancer as well as producing method |
| CN1582995A (en) * | 2004-06-15 | 2005-02-23 | 河北以岭医药研究院有限公司 | Preparation of medicinal composition for nourishing |
-
2005
- 2005-11-07 CN CNB2005101155693A patent/CN100348259C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1539458A (en) * | 2003-10-30 | 2004-10-27 | 吉林省辽源亚东药业股份有限公司 | Chinese materia medica preparation made from gen-seng and astragalus root for strengthening the body resistance and anti cancer as well as producing method |
| CN1582995A (en) * | 2004-06-15 | 2005-02-23 | 河北以岭医药研究院有限公司 | Preparation of medicinal composition for nourishing |
Non-Patent Citations (2)
| Title |
|---|
| 中医及中西医结合治疗放化疗后白细胞减少症 张文芳等.现代中西医结合杂志，第11卷第24期 2002 * |
| 中药抗肿瘤免疫的研究进展 杜鹃.中医药临床杂志，第16卷第5期 2004 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1772268A (en) | 2006-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103719498A (en) | Immunity-enhancing sealwort health-care tea and preparation method thereof | |
| CN104740541B (en) | A kind of protecting liver and detoxication restores the Chinese medicine powder for health care of liver function | |
| CN105434842A (en) | Traditional Chinese medicine composition for strengthening immunity and improving sleep as well as preparation and preparation method thereof | |
| CN102697903A (en) | Medicine for treating herpes zoster | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN108813610B (en) | Saussurea involucrate composition for improving immunity and application thereof | |
| CN105664140A (en) | Glycopeptide composition as well as preparation method and application thereof | |
| CN100348259C (en) | Medicine composition for raising immunity and its prepn and application | |
| CN106038702B (en) | Antifatigue composition and its preparation method and application | |
| CN101317900B (en) | Chinese medicinal composition for preventing and controlling alcoholic liver damnification and preparation method thereof | |
| CN102631492B (en) | Chinese medicinal composition for improving immunity and resisting fatigue | |
| CN101690746B (en) | Chinese herbal preparation for treating soft tissue injuries and fractures | |
| CN101229272A (en) | Medicine compounds for increasing immunizing-power, preparing method and applications thereof | |
| CN102631506B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN102631486B (en) | Health care composition | |
| CN102631487B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN106421154A (en) | Traditional Chinese medicine composition and traditional Chinese medicine preparation containing Chinese eaglewood wood and having cell repairing, anti-aging and anti-canter functions as well as preparation method of traditional Chinese medicine composition | |
| CN102631493B (en) | Health care composition | |
| CN1593645A (en) | Anticancer medicine and its preparation | |
| CN102631393B (en) | Health care composition | |
| CN102631489B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN114767798A (en) | Liver-protecting fat-reducing oral liquid and preparation method thereof | |
| CN102526248A (en) | Traditional Chinese medicine prescription capable of curing diabetes wound fester and continuously reducing blood sugar | |
| NL2037306A (en) | A nutritional product for clearing and protecting the lungs and a preparation method thereof | |
| CN113663024A (en) | Traditional Chinese medicine composition for treating viral myocarditis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071114 Termination date: 20161107 |